4.2 Article

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence

期刊

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
卷 12, 期 3, 页码 160-187

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/15622975.2011.561872

关键词

Opioid dependence; buprenorphine; clonidine; heroin; lofexidine; methadone; naloxone; naltrexone; maintenance treatment

资金

  1. Eli Lilly
  2. Bristol-Myers Squibb
  3. AstraZeneca
  4. Sanofi-Aventis Essex
  5. Prempharm
  6. Janssen
  7. Schering Plough
  8. Lundbeck
  9. Alkermes
  10. GlaxoSmithKline
  11. Abbott
  12. Johnson Johnson
  13. ACTIVE
  14. Abbott Laboratories
  15. Aisling Capital LLC
  16. AstraZeneca Pharmaceuticals
  17. Brintnall Nicolini, Inc.
  18. Easton Associates
  19. Eisai Inc.
  20. Eli Lilly and Co.
  21. F. Hoffmann-La Roche Ltd
  22. Gilead Sciences Inc.
  23. Janssen Pharmaceuticals
  24. Lohocla Research Corporation
  25. Lundbeck Research USA
  26. Medivation Inc.
  27. Merz Pharmaceuticals
  28. MK Medical Communications
  29. Naurex Inc.
  30. Pfizer Pharmaceuticals
  31. SK Holdings Co. Ltd
  32. Takeda Industries
  33. Tetragenex Pharmaceuticals
  34. Teva Pharmaceutical Industries Ltd.
  35. Eisai
  36. Janssen Cilag
  37. Merck
  38. Novartis
  39. Organon
  40. Pfizer
  41. Sanofi-Aventis
  42. Schering-Plough
  43. Schwabe
  44. Sepracor
  45. Servier
  46. Wyeth

向作者/读者索取更多资源

Objectives. To develop evidence-based practice guidelines for the pharmacological treatment of opioid abuse and dependence. Methods. An international task force of the World Federation of Societies of Biological Psychiatry (WFSBP) developed these practice guidelines after a systematic review of the available evidence pertaining to the treatment of opioid dependence. On the basis of the evidence, the Task Force reached a consensus on practice recommendations, which are intended to be clinically and scientifically meaningful for physicians who treat adults with opioid dependence. The data used to develop these guidelines were extracted primarily from national treatment guidelines for opioid use disorders, as well as from meta-analyses, reviews, and publications of randomized clinical trials on the efficacy of pharmacological and other biological treatments for these disorders. Publications were identified by searching the MEDLINE database and the Cochrane Library. The literature was evaluated with respect to the strength of evidence for efficacy, which was categorized into one of six levels (A--F). Results. There is an excellent evidence base supporting the efficacy of methadone and buprenorphine or the combination of buprenorphine and naloxone for the treatment of opioid withdrawal, with clonidine and lofexidine as secondary or adjunctive medications. Opioid maintenance with methadone and buprenorphine is the best-studied and most effective treatment for opioid dependence, with heroin and naltrexone as second-line medications. Conclusions. There is enough high quality data to formulate evidence-based guidelines for the treatment of opioid abuse and dependence. This task force report provides evidence for the efficacy of a number of medications to treat opioid abuse and dependence, particularly the opioid agonists methadone or buprenorphine. These medications have great relevance for clinical practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据